Global Alliance for TB Drug Development

Quick facts

Marketed products

• HR · Infectious Disease
  HR is a fixed-dose combination of isoniazid and rifampicin used to treat tuberculosis by inhibiting bacterial cell wall and RNA synthesis.
• Moxifloxacin (M) · Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.

Phase 3 pipeline

• HRZE · Infectious Disease
  HRZE is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production.
• Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin · Infectious Disease
  This is a fixed-dose combination of five anti-tuberculosis agents that work through multiple mechanisms to inhibit bacterial cell wall synthesis, protein synthesis, and DNA replication in Mycobacterium tuberculosis.
• Pyrazinamide (Z) · Infectious Disease
  Pyrazinamide is converted to pyrazinoic acid inside Mycobacterium tuberculosis cells, where it disrupts bacterial energy metabolism and nucleic acid synthesis.

Phase 2 pipeline

• Rifafour · Other
• TMC207

Phase 1 pipeline

• TBAJ-876 suspension
• TBI-223 enteric capsule
• TBI-223 IR Tablet
• TBI-223 oral suspension
• TBI-223 SR Tablet Prototype 1
• TBI-223 SR Tablet Prototype 2
• TBI-223 SR Tablet Prototype 3

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Global Alliance for TB Drug Development portfolio CI brief
• Global Alliance for TB Drug Development pipeline updates RSS